Morgan Stanley Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $675.00

Axon Enterprise (NASDAQ:AXON) had its price objective trimmed by Morgan Stanley from $713.00 to $675.00 in a research note published on Wednesday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on AXON. Royal Bank Of Canada reduced their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday. Barclays reduced their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a research note on Wednesday. Craig Hallum restated a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a report on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Finally, Piper Sandler reduced their price target on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Price Performance

Shares of AXON opened at $542.40 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock has a market cap of $43.61 billion, a PE ratio of 356.84, a PEG ratio of 16.57 and a beta of 1.48. Axon Enterprise has a 12-month low of $396.41 and a 12-month high of $885.91. The business has a 50-day simple moving average of $537.92 and a two-hundred day simple moving average of $625.54.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. During the same period in the previous year, the business posted $2.08 earnings per share. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. Analysts anticipate that Axon Enterprise will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the sale, the chief executive officer owned 3,110,997 shares in the company, valued at $1,717,021,464.24. This represents a 0.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brittany Bagley sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the sale, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at $60,030,580. This represents a 1.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 58,040 shares of company stock worth $32,251,738 over the last three months. Insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Large investors have recently bought and sold shares of the stock. Baillie Gifford & Co. grew its stake in shares of Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares during the period. Edgewood Management LLC bought a new position in shares of Axon Enterprise in the fourth quarter valued at $846,516,000. Wellington Management Group LLP increased its position in shares of Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after acquiring an additional 1,179,038 shares in the last quarter. Norges Bank bought a new position in Axon Enterprise in the 4th quarter valued at about $515,764,000. Finally, Vestor Capital LLC boosted its stake in Axon Enterprise by 438,636.3% during the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after purchasing an additional 833,409 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.